219 research outputs found
X-rays Activate Telomeric Homologous Recombination Mediated Repair in Primary Cells
No full textCancer cells need to acquire telomere maintenance mechanisms in order to counteract progressive telomere shortening due to multiple rounds of replication. Most human tumors maintain their telomeres expressing telomerase whereas the remaining 15%-20% utilize the alternative lengthening of telomeres (ALT) pathway. Previous studies have demonstrated that ionizing radiations (IR) are able to modulate telomere lengths and to transiently induce some of the ALT-pathway hallmarks in normal primary fibroblasts. In the present study, we investigated the telomere length modulation kinetics, telomeric DNA damage induction, and the principal hallmarks of ALT over a period of 13 days in X-ray-exposed primary cells. Our results show that X-ray-treated cells primarily display telomere shortening and telomeric damage caused by persistent IR-induced oxidative stress. After initial telomere erosion, we observed a telomere elongation that was associated to the transient activation of a homologous recombination (HR) based mechanism, sharing several features with the ALT pathway observed in cancer cells. Data indicate that telomeric damage activates telomeric HR-mediated repair in primary cells. The characterization of HR-mediated telomere repair in normal cells may contribute to the understanding of the ALT pathway and to the identification of novel strategies in the treatment of ALT-positive cancers
Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in doberman pinschers with preclinical dilated cardiomyopathy (the PROTECT study)
No full text<p>Background: The benefit of pimobendan in delaying the progression of preclinical dilated cardiomyopathy (DCM) in Dobermans is not reported.</p>
<p>Hypothesis: That chronic oral administration of pimobendan to Dobermans with preclinical DCM will delay the onset of CHF or sudden death and improve survival.</p>
<p>Animals: Seventy-six client-owned Dobermans recruited at 10 centers in the UK and North America.</p>
<p>Methods: The trial was a randomized, blinded, placebo-controlled, parallel group multicenter study. Dogs were allocated in a 1:1 ratio to receive pimobendan (Vetmedin capsules) or visually identical placebo.</p>
<p>The composite primary endpoint was prospectively defined as either onset of CHF or sudden death. Time to death from all causes was a secondary endpoint.</p>
<p>Results: The proportion of dogs reaching the primary endpoint was not significantly different between groups (P = .1). The median time to the primary endpoint (onset of CHF or sudden death) was significantly longer in the pimobendan (718 days, IQR 441–1152 days) versus the placebo group (441 days, IQR 151–641 days) (log-rank P = 0.0088). The median survival time was significantly longer in the pimobendan (623 days, IQR 491–1531 days) versus the placebo group (466 days, IQR 236–710 days) (log-rank P = .034).</p>
<p>Conclusion and Clinical Importance: The administration of pimobendan to Dobermans with preclinical DCM prolongs the time to the onset of clinical signs and extends survival. Treatment of dogs in the preclinical phase of this common cardiovascular disorder with pimobendan can lead to improved outcome.</p>
Prospective evaluation of NT-proBNP assay to detect occult dilated cardiomyopathy and predict survival in Doberman Pinschers
No full text
Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: The QUEST study
No full textBackground: Myxomatous mitral valve disease (MMVD) continues to be an important cause of morbidity and mortality in geriatric dogs despite conventional therapy
Pancreatectomy with synchronous vascular resection - An argument in favour
No full textBackground: The first case-series of pancreatectomy with synchronous en-bloc vascular resection with the aim to improve pancreatic cancer survival was published in 1977. Advances in surgical techniques, intensive care management and teaching centers with high volume cases have dramatically reduced mortality and morbidity of major pancreatic resections. This has led to a progressively wider use of venous and-or arterial resections during pancreatic surgery in selected patients to achieve negative resection margins. Methods: We review the current literature and discuss our experience in pancreatectomies with en-bloc vascular resections. Results: Survival of patients with pancreatic cancer who undergo an R0 resection with venous reconstruction is comparable to those who have a standard pancreaticoduodenectomy with no added mortality or morbidity. Conversely, arterial resection is associated with a higher morbidity, mortality and overall poorer survival, perhaps reflecting more advanced disease. Conclusions: Since the need for vascular resection may not be always apparent on pre-operative imaging, surgeons who perform major pancreatic surgery should be familiar with vascular resection and reconstruction techniques in order to offer to these patients the best chance to prolong survival. © 2011 Royal College of Surgeons of Edinburgh (Scottish charity number SC005317) and Royal College of Surgeons in Ireland.Ahmad NA, 2001, J CLIN GASTROENTEROL, V32, P54, DOI 10.1097-00004836-200101000-00013; ALLEMA JH, 1995, CANCER, V75, P2069, DOI 10.1002-1097-0142(19950415)75:82069::AID-CNCR28207508073.0.CO;2-7; Andersson R, 2004, HPB (Oxford), V6, P5, DOI 10.1080-13651820310017093; Cameron JL, 2006, ANN SURG, V244, P10, DOI 10.1097-01.sla.0000217673.04165.ea; CUSACK JC, 1994, AM J SURG, V168, P352, DOI 10.1016-S0002-9610(05)80164-3; FERNANDEZDELCASTILLO C, 1995, ARCH SURG-CHICAGO, V130, P295; FORTNER JG, 1977, ANN SURG, V186, P42, DOI 10.1097-00000658-197707000-00007; Fuhrman GM, 1996, ANN SURG, V223, P154, DOI 10.1097-00000658-199602000-00007; Fukuda Saburo, 2007, Arch Surg, V142, P172, DOI 10.1001-archsurg.142.2.172; Gress FG, 1999, GASTROINTEST ENDOSC, V50, P786, DOI 10.1016-S0016-5107(99)70159-8; Harrison LE, 1996, ANN SURG, V224, P342, DOI 10.1097-00000658-199609000-00010; Helmstaedter L, 2008, LANGENBECK ARCH SURG, V393, P923, DOI 10.1007-s00423-007-0275-1; Hirano S, 2007, ANN SURG, V246, P46, DOI 10.1097-01.sla.0000258608.52615.5a; ISHIKAWA O, 1992, ANN SURG, V215, P231, DOI 10.1097-00000658-199203000-00006; Kaneko T, 1998, SEMIN SURG ONCOL, V15, P47, DOI 10.1002-(SICI)1098-2388(199807-08)15:147::AID-SSU83.0.CO;2-W; KAYAHARA M, 1991, INT J PANCREATOL, V10, P105; Leach SD, 1998, BRIT J SURG, V85, P611; Lillemoe KD, 1999, ANN SURG, V229, P693, DOI 10.1097-00000658-199905000-00012; Misuta K, 2005, J GASTROINTEST SURG, V9, P245, DOI 10.1016-j.gassur.2004.06.003; NAGAKAWA T, 1993, BRIT J SURG, V80, P619, DOI 10.1002-bjs.1800800526; Nakagohri T, 2003, AM J SURG, V186, P149, DOI 10.1016-S0002-9610(03)00173-9; NAKAO A, 1995, SURGERY, V117, P50, DOI 10.1016-S0039-6060(05)80229-6; Nakao A, 2006, WORLD J SURG, V30, P976, DOI 10.1007-s00268-005-0438-6; NITECKI SS, 1995, ANN SURG, V221, P59, DOI 10.1097-00000658-199501000-00007; Richter A, 2003, WORLD J SURG, V27, P324, DOI 10.1007-s00268-002-6659-z; Schneider G, 2005, GASTROENTEROLOGY, V128, P1606, DOI 10.1053-j.gastro.2005.04.001; Schniewind B, 2006, ANN SURG ONCOL, V13, P1403, DOI 10.1245-s10434-006-9172-z; Sener SF, 1999, J AM COLL SURGEONS, V189, P1, DOI 10.1016-S1072-7515(99)00075-7; Shimada K, 2006, ANN SURG ONCOL, V13, P1569, DOI 10.1245-s10434-006-9143-4; Siriwardana HPP, 2006, BRIT J SURG, V93, P662, DOI 10.1002-bjs.5368; Sohn TA, 2000, J GASTROINTEST SURG, V4, P567, DOI 10.1016-S1091-255X(00)80105-5; Stein M, 2002, J VASC INTERV RADIOL, V13, P805, DOI 10.1016-S1051-0443(07)61990-3; Stitzenberg KB, 2008, ANN SURG ONCOL, V15, P1399, DOI 10.1245-s10434-008-9844-y; Takahashi S, 2004, HEPATO-GASTROENTEROL, V47, P545; TREDE M, 1990, ANN SURG, V211, P447, DOI 10.1097-00000658-199004000-00011; TSAO JI, 1994, ARCH SURG-CHICAGO, V129, P405; Tseng JF, 2004, J GASTROINTEST SURG, V8, P935, DOI 10.1016-j.gassur.2004.09.046; Wagner M, 2004, BRIT J SURG, V91, P586, DOI 10.1002-bjs.4484; Yekebas EF, 2008, ANN SURG, V247, P300, DOI 10.1097-SLA.0b013e31815aab22; Yeo CJ, 1997, ANN SURG, V226, P248, DOI 10.1097-00000658-199709000-0000413
The digital search for meaning: an interview with Michael Maguire
No full textI met and spoke with Michael J. Maguire, one of Ireland’s most prominent—if not the most prominent—author of electronic literature
The Ryanline is Now Open: Talk Radio and the Public Sphere
No full textAuthor has checked copyrightCopyright rested with author so I presume I can archive i
Australian-wide apatite fission track data compilation
No full textThis dataset comprises 1785 apatite fission track (AFT) analyses from mostly Archaean-Palaeozoic igneous rocks, or their metamorphic equivalent, from across the Australian continent. Information provided in this dataset include sample locations, lithologies, AFT age determinations, and mean confined track length measurements. These analyses were first described in Kohn et al. (2002) and Gleadow et al. (2002), and provide critical insights into the low-temperature tectono-thermal evolution of the Australian upper crust over the last 300 million years
- …
